Diaceutics PLC

Good afternoon and welcome to today's webinar hosted by Diocytics to discuss the company's full year 2025 results issued earlier today. My name is Simon Guilon and I manage Diocytics IOR program. On the call today to discuss the results are Ryan Keeling, CEO and Nick Roberts, CFO. Before I hand it over to Ryan for his formal remarks, I would draw your attention to the forward looking statement slide in our presentation, which is on screen now and can also be downloaded at diocytics.com. At this time, I will now turn the call over to Ryan. Ryan, please go ahead.

Thank you, Simon. Good afternoon.

Good morning, everybody. From a very warm, should I say hot London, where we are on day one of our Investor Roadshow. Delighted you all could make some time to be with us today. And Nick and I are going to I'll walk you through the highlights of 2025, of which there are many. I wanted to start at maybe taking a step back and looking at the 25 year as a whole. It was an important year for Dynastatics and in many ways a validating year for the model. We delivered 20% revenue growth, that was 24% of constant currency. in what was probably the most challenging commercial environment we've experienced in the US pharma market certainly in the time trading history of diastetics. But despite that disruption across the sector particularly through Q2 and Q3 where we saw quite significant shifts in policy and ultimately the operating environment for our customers We still felt we put in a very strong year. We expanded ARR by 19%. We increased our adjusted EBITDA by 80% to £7.6 million. We delivered a 20% EBITDA margin and returned the business to profitability. More importantly, and very aligned to the strategy that we're on as a business, the quality and visibility of the revenue base continue to improve. We closed the year with a record 38.9 million pounds in order book, including 21.1 million visibility into FY26, giving us increased visibility over the year's revenue and indeed 27 and 28 are also building well. We also grew alongside subscription revenue, enterprise engagements and PMX adoption. All of these will get into more detail in a moment. Strategically, the business strengthened meaningfully during the year. We now have 10 enterprise wide farm engagements. We work across 95 brands and 53 customers and we signed our second PMX customer. Really symbolic for us and we'll talk a lot more today about PMX. It has a real halo effect on the business and is dragging up the average revenue per brand across the portfolio. and behind PMX, we now have a pipeline of 24 potential PMX opportunities and really heartened to see that eight of those are already spending with us today. They're not spending at PMX levels. We can't call them PMX customers yet, but the strategy there is to to grow these customers that we have identified as PMX targets. We're having that conversation with them. We've pitched PMX to them from day one. These are biotechs predominantly, and we believe that we can convert a sizable number of those into full-blown PMX opportunities, whether we are extracting two, three, four million dollars per year average revenue. We also continue to invest deliberately in the long-term scalability and strategic value of the platform, particularly through US focused data assets and support our precision for all strategy. We'll talk a lot about precision for all. It's a very exciting growth opportunity. You heard us last year talk about the TAM expansion and what we saw there. Precision for all is really the further articulated view on what that time expansion could look like and we have a lot of validation now through existing sales into customers that are embracing that precision for all approach. Nick is going to walk through the financials in more detail including cash working capital I know that's a key area to dig into today as per some of the analyst notes that are out and we'll get into that but at a high level we view 25 as a year where the business became more recurring more visible more profitable and more strategically embedded with customers the fundamentals of this business are really going from strength to strength and we exit the year stronger. I said we have more customers, more brands, more recurring revenue, higher visibility, expanding margins and a significantly larger long-term addressable market opportunity. Sets us up really well for continued growth, continued success and as we dive more into the financials and ultimately the narrative, we can bring some of this to life for you. I'm going to pass now to Nick, my CFO, to walk you through some of the financials. Next slide, Simon, thank you. Over to you, Nick.